Impact of rosuvastatin on metabolic syndrome patients with moderate to severe metabolic associated fatty liver disease without overt diabetes: A randomized clinical trial
Rosuvastatin significantly reduced hepatic steatosis in individuals with moderate to severe MAFLD and metabolic syndrome over 52 weeks, while maintaining a favorable safety profile.
Authors
- Yuxiu Li (ORCID: https://orcid.org/0000-0002-5227-421X)
- Lu Lyu (ORCID: https://orcid.org/0000-0002-1874-840X)
- Huabing Zhang (ORCID: https://orcid.org/0000-0001-6259-7584)
- Fan Ping
- Shitian Wang
- Wei Li (ORCID: https://orcid.org/0000-0002-3332-1287)
- Lingling Xu (ORCID: https://orcid.org/0000-0003-2731-4758)
- Yiwen Liu (ORCID: https://orcid.org/0000-0002-7982-7996)
- Xuan Wang (ORCID: https://orcid.org/0009-0008-0390-8141)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Diabetes & Metabolic Syndrome Clinical Research & Reviews
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.dsx.2024.103126
- Citations
- 7
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- AstraZeneca